
In 2 pivotal phase 3 studies, all 5 readers hit sensitivity and specificity targets for florquinitau F 18 tau PET, including in patients with early symptomatic Alzheimer disease.
The studies discussed in this slideshow assess the benefits of non-traditional therapies for depressive disorders.
1. Falconer CJ, Rovira A, King JA, et al.
2. Macy RJ, Jones E, Graham LM, Roach L.
3. Centre for Addiction and Mental Health.



